Your browser doesn't support javascript.
loading
An update on novel therapies for treating patients with arterial thrombosis.
Tantry, Udaya S; Duhan, Sanchit; Navarese, Eliano; Ramotowski, Bogumil; Kundan, Parshotam; Bliden, Kevin P; Gurbel, Paul.
Afiliación
  • Tantry US; Sinai Center for Thrombosis Research, Sinai Hospital of Baltimore, Baltimore, MD, USA.
  • Duhan S; Sinai Center for Thrombosis Research, Sinai Hospital of Baltimore, Baltimore, MD, USA.
  • Navarese E; Interventional Cardiology and Cardiovascular Medicine Research, Department of Cardiology and Internal Medicine, Nicolaus Copernicus University, Bydgoszcz, Poland.
  • Ramotowski B; Department of Cardiology, Centre of Postgraduate Medical Education, Warsaw, Poland.
  • Kundan P; Sinai Center for Thrombosis Research, Sinai Hospital of Baltimore, Baltimore, MD, USA.
  • Bliden KP; Sinai Center for Thrombosis Research, Sinai Hospital of Baltimore, Baltimore, MD, USA.
  • Gurbel P; Sinai Center for Thrombosis Research, Sinai Hospital of Baltimore, Baltimore, MD, USA.
Expert Rev Hematol ; 16(8): 593-605, 2023.
Article en En | MEDLINE | ID: mdl-37335893
INTRODUCTION: Antithrombotic therapy field is undergoing rapid and significant changes during the past decade. In addition to new therapeutic strategies with existing targets, investigators are exploring the potential use of new targets to address unmet needs to treat patients with arterial diseases. AREAS COVERED: We aim to provide an update on and a comprehensive review of the antithrombic agents that are being explored in patients with arterial diseases. We discuss latest developments with respect to upstream antiplatelet agents, and collagen and thrombin pathway inhibitors. We searched PubMed databases for English language articles using keywords: antiplatelet agents, thrombin pathway inhibitors, collagen receptors, arterial disease. EXPERT OPINION: Despite implementation of potent P2Y12 inhibitors, there are numerous unmet needs in the treatment of arterial diseases including ceiling effect of currently available antiplatelet agents along with and an elevated risk of bleeding. The latter observations encouraged investigators to explore new targets that can attenuate the generation of platelet-fibrin clot formation and subsequent ischemic event occurrences with minimal effect on bleeding. These targets include collagen receptors on platelets and thrombin generation including FXa, FXIa, and FXIIa. In addition, investigators are studying novel antiplatelet agents/strategies to facilitate upstream therapy in high-risk patients.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Trombosis / Inhibidores de Agregación Plaquetaria Límite: Humans Idioma: En Revista: Expert Rev Hematol Asunto de la revista: HEMATOLOGIA Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Trombosis / Inhibidores de Agregación Plaquetaria Límite: Humans Idioma: En Revista: Expert Rev Hematol Asunto de la revista: HEMATOLOGIA Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido